1-3 of 3
Kristi A Boehm, MS
Close
Sort by
Journal Articles

Results of a Phase II Study of Bortezomib in Patients with Relapsed or Refractory Indolent Lymphoma.

Nicholas Di Bella, MD, Raymond Taetle, MD, Kathryn S. Kolibaba, MD, Thomas E Boyd, MD, Robert N Raju, MD, David N Barrera, DO, Ernest Cochran, MD, Philip Dien, MD, David Hakimian, MD, Roger M. Lyons, MD, Peter J Schlegel, MD, Svetislava J Vukelja, MD, Julie Boston, RN, Kristi A Boehm, MS, Yunfei Wang, MS, Lina Asmar, PhD
Journal: Blood
Blood (2008) 112 (11): 1572.
https://doi.org/10.1182/blood.V112.11.1572.1572
Published: 2008
Journal Articles

Phase III Trial of Fludarabine, Cyclophosphamide, and Rituximab Vs. Pentostatin, Cyclophosphamide, and Rituximab in B-Cell Chronic Lymphocytic Leukemia

Craig Reynolds, MD, Nicholas Di Bella, MD, Roger M. Lyons, MD, William J Hyman, MD, Gary L. Lee, MD, Donald A Richards, MD, PhD, Gerald J. Robbins, MD, Mark Vellek, MD, Kristi A Boehm, MS, Feng Zhan, PhD, Lina Asmar, PhD
Journal: Blood
Blood (2008) 112 (11): 327.
https://doi.org/10.1182/blood.V112.11.327.327
Published: 2008
Journal Articles

Results of a Randomized Phase II Trial of Pegfilgrastim Versus Filgrastim To Treat Neutropenia Post-Autologous Peripheral Blood Stem Cell Transplant (PBSCT) in Patients with Non-Hodgkin’s Lymphoma (NHL).

Robert Rifkin, MD, Roy Beveridge, MD, Gary Spitzer, MD, Gregory Orloff, MD, Romeo Mandanas, MD, Dean McGaughey, MD, Mark Brunvand, MD, Feng Zhan, PhD, Kristi A. Boehm, MS, Lina Asmar, PhD
Journal: Blood
Blood (2007) 110 (11): 4936.
https://doi.org/10.1182/blood.V110.11.4936.4936
Published: 2007